Shire announced an FDA approval for Intuniv (guanfacine) Extended Release Tablets yesterday, and is preparing professional advertising efforts for a November launch, with “closely aligned” consumer ads to follow in 2010.
Only a tenth of scripts are up for grabs, says IMS study
Traditional promotion efforts, including details and sampling, can only affect about 10% of prescriptions, an IMS study found, suggesting that the bulk of promotion dollars is misplaced.
Pfizer aims to differentiate Toviaz with patient support program
Pfizer is launching Detrol follow-on Toviaz with a 12-week patient support program featuring a progress tracker, personalized emails and tips on bladder training techniques. The company said many overactive bladder patients currently suffer from a lack of behavioral intervention.
Monthly Prescribing Reference (MPR) has relaunched its website with a number of enhancements to functionality and design, as well as a new, easier-to-remember URL, www.eMPR.com.
DTC spend lags as firms scrimp on launches, says TNS
Spending on direct-to-consumer launch campaigns fell significantly this year as companies waited longer to market fewer new drugs with more limited indications, said a TNS Media Intelligence report.
Top 20% of endocrinologists write lion’s share of new oral diabetes scripts: SDI
Identifying physicians who drive the new-to-brand market in a given category — prior to developing a marketing strategy – allows marketers to save time and money by avoiding docs with tin ears.
Researches involved in the litigation against Vioxx claim the product’s ADVANTAGE trials were based on marketing objectives rather than scientific rigor.
Thomson Reuters names five most promising Q1 drugs
A Thomson Reuters study forecasts five of the “most promising drugs launched or receiving approval” during the first quarter of 2008.
Company news
May 20, 2008
6:32 pm
Quadrant HealthCom is targeting nurse practitioners and physician assistants with its launch of Convenient Care, the official journal of the Convenient Care Association.
The decision by Sepracor to in-license the US marketing rights to inhaled corticosteroid Alvesco caps a four-year commercial and regulatory odyssey for the asthma drug.